Appendix 3B

New Issue Announcement, Application for Quotation of Additional Securities and Agreement

Information or documents not available now must be given to ASX as soon as available. Information and documents given to ASX become ASX's property and may be made public.

Introduced 01/07/96 Origin: Appendix 5 Amended 01/07/98, 01/09/99, 01/07/00, 30/09/01, 11/03/02, 01/01/03, 24/10/05, 01/08/12, 04/03/13

Immu	Immuron Limited (ASX: IMC) (NASDAQ: IMRN)		
ABN			
80 063	3 114 045		
We (th	he entity) give ASX the following information		
	: 1 - All issues ust complete the relevant sections (attach sheets if there	e is not enough space).	
1	⁺ Class of ⁺ securities issued or to be issued	Ordinary Shares (IMC)	
2	Number of ⁺ securities issued or to be issued (if known) or maximum number which may be issued	399,045	
3	Principal terms of the *securities (e.g. if options, exercise price and expiry date; if partly paid *securities, the amount outstanding and due dates for payment; if *convertible securities, the conversion price and dates for conversion)	Ordinary Fully Paid Shares (IMC)	

Name of Entity

4	Do the *securities rank equally in all respects from the *issue date with an existing *class of quoted *securities? If the additional *securities do not rank	Yes (IMC)
	 equally, please state: the date from which they do the extent to which they participate for the next dividend, (in the case of a trust, distribution) or interest payment the extent to which they do not rank equally, other than in relation to the next dividend, distribution or interest payment 	
5	Issue price or consideration	\$75,333.35
6	Purpose of the issue (If issued as consideration for the acquisition of assets, clearly identify those assets)	Repayment of Convertible Note Security in accordance with executed funding agreement with a New York based Investment fund provider announced to the ASX on 17 th Feb 2016.
6a	Is the entity an *eligible entity that has obtained security holder approval under rule 7.1A?	Yes
	If Yes, complete sections 6b – 6h <i>in relation to the</i> *securities the subject of this Appendix 3B, and comply with section 6i	
6b	The date the security holder resolution under rule 7.1A was passed	29 November 2016
6c	Number of *securities issued without security holder approval under rule 7.1	399,045 Ordinary Fully Paid Shares (IMC)
6d	Number of *securities issued with security holder approval under rule 7.1A	Nil
6e	Number of *securities issued with security holder approval under rule 7.3, or another specific security holder approval (specify date of meeting)	Nil
6f	Number of *securities issued under an exception in rule 7.2	Nil
6g	If *securities issued under rule 7.1A, was issue price at least 75% of 15 day VWAP as calculated under rule 7.1A.3? Include the *issue date and both values. Include the source of the VWAP calculation.	N/A

6h If *securities were issued under rule 7.1A for non-cash consideration, state date on which valuation of consideration was released to ASX Market Announcements N/A

6i Calculate the entity's remaining issue capacity under rule 7.1 and rule 7.1A – complete Annexure 1 and release to ASX Market Announcements

Refer to the attached Appendix 1

7 +Issue dates

Note: The issue date may be prescribed by ASX (refer to the definition of issue date in rule 19.12). For example, the issue date for a pro rata entitlement issue must comply with the applicable timetable in Appendix 7A.

Cross reference: item 33 of Appendix 3B.

28 July 2017

8 Number and *class of all *securities quoted on ASX (*including* the *securities in section 2 if applicable)

Number	⁺ Class
128,440,462*	Fully Paid Ordinary Shares (IMC)
2,000,000	Fully Paid Ordinary Shares (IMC) held in escrow as security for any repayment default of the Convertible Loan.
	These will either be purchased by the Investor or cancelled at end of agreement.
25,289,894	Listed Options (IMCOB) exercisable at A\$0.55 on or before 30 Nov 2019

^{*} This number does not include 3,660,000 shares (91,500 ADSs) which, pursuant to the ASX announcement on 9 June 2017, may be issued for any over-allocations under the NASDAQ IPO listing.

9 Number and *class of all *securities not quoted on ASX (including the *securities in section 2 if applicable)

Qty	Qty +Class (Options over Ordinary Shares)		
Amount	Exercise	Expiration	ASX Code
	Price	Date	
62,500	AUD\$1.556	1 Nov 2017	IMCSO2
1,050,000	AUD\$0.500	1 Oct 2018	IMCAC
1,000,000	AUD\$0.570	24 Feb 2019	IMCAI
15,380	AUD\$1.892	28 Feb 2019	IMCAI
140,056	AUD\$0.300	28 May 2019	IMCAI
7,625,532*	AUD\$0.500	27 Nov 2019	IMCAI
14,493	AUD\$1.944	30 Nov 2021	IMCRM1
29,668	AUD\$1.876	17 Jan 2022	IMCRM2
28,060,000	USD\$10.00 for	13 Jun 2022	IMCAI
(701,500 Warrants)	every 40 options		
37,997,629	Total		

^{*1,000,000} of these options are subject to shareholder approval and will be tabled at the next members meeting.

9 Number and *class of all *securities Qtv +Class (Convertible Notes - IMCAA) not quoted on ASX (including the 150,667 A\$150,667 Face Value Convertible Note *securities in section 2 if applicable) repayable over a remaining 2 mth period settled at the Company's discretion by way of either: - the issuance of new Shares at a 10% discount to VWAP average price of any 5 days over the 20 days immediately prior to a repayment - a cash repayment of the due amount plus a 2.5% premium. 10 Dividend policy (in the case of a Unchanged trust, distribution policy) on the increased capital (interests) Part 2 - Pro rata issue 11 security holder approval required? 12 Is the issue renounceable or nonrenounceable? 13 Ratio in which the *securities will be offered *Class of *securities to which the 14 offer relates 15 ⁺Record date to determine entitlements Will holdings on different registers 16 (or sub-registers) be aggregated for calculating entitlements? 17 Policy for deciding entitlements in relation to fractions 18 Names of countries in which the entity has security holders who will not be sent new offer documents Note: Security holders must be told how their entitlements are to be dealt with. Cross reference: rule 7.7.

Closing date for

acceptances or renunciations

receipt

of

19

⁺ See chapter 19 for defined terms. 07/07/2016

20	Names of any underwriters	-
21	Amount of any underwriting fee or commission	-
22	Names of any brokers to the issue	-
23	Fee or commission payable to the broker to the issue	-
24	Amount of any handling fee payable to brokers who lodge acceptances	-
	or renunciations on behalf of security holders	
25	If the insue is restinged.	
25	If the issue is contingent on security holders' approval, the date of the meeting	-
26	Date entitlement and acceptance form and offer documents will be sent to persons entitled	-
	some to person on the control	
27	If the entity has issued options, and	
21	the terms entitle option holders to participate on exercise, the date on	-
	which notices will be sent to option holders	
28	Date rights trading will begin (if applicable)	-
29	Date rights trading will end (if applicable)	-
30	How do security holders sell their entitlements <i>in full</i> through a broker?	-
31	How do security holders sell <i>part</i> of their entitlements through a broker	-
	and accept for the balance?	
	·	
32	How do security holders dispose of	_
32	their entitlements (except by sale through a broker)?	
	(
33	†Issue date	_
JJ	ושטער עמוב	<u>-</u>

Part 3 - Quotation of securities

You need only complete this section if you are applying for quotation of securities

34	Type of *securities (tick one)
(a)	*Securities described in Part 1
(b)	All other *securities Example: restricted securities at the end of the escrowed period, partly paid securities that become fully paid, employee incentive share securities when restriction ends, securities issued on expiry or conversion of convertible securities
ntitie	s that have ticked box 34(a)
Additio	nal securities forming a new class of securities
Tick to	indicate you are providing the information or documents
35	If the *securities are *equity securities, the names of the 20 largest holders of the additional *securities, and the number and percentage of additional *securities held by those holders
36	If the *securities are *equity securities, a distribution schedule of the additional *securities setting out the number of holders in the categories 1 - 1,000 1,001 - 5,000 5,001 - 10,000 10,001 - 100,000 100,001 and over
37	A copy of any trust deed for the additional *securities

Entities that have ticked box 34(b)

38	Number of *securities for which *quotation is sought		
39	⁺ Class of ⁺ securities for which quotation is sought		
40	Do the *securities rank equally in all respects from the *issue date with an existing *class of quoted *securities?		
	If the additional *securities do not rank equally, please state:		
	 the date from which they do the extent to which they participate for the next dividend, (in the case of a trust, distribution) or interest payment 		
	 the extent to which they do not rank equally, other than in relation to the next dividend, distribution or interest payment 		
41	Reason for request for quotation now		
	Example: In the case of restricted securities, end of restriction period		
	(if issued upon conversion of another *security, clearly identify that other *security)		
		Number	+Class
42	Number and *class of all *securities quoted on ASX	Number	Ciass
42	lincluding the *securities in clause 38)		

+ See chapter 19 for defined terms. 07/07/2016

Quotation agreement

- ⁺Quotation of our additional ⁺securities is in ASX's absolute discretion. ASX may quote the ⁺securities on any conditions it decides.
- 2 We warrant the following to ASX.
 - The issue of the ⁺securities to be quoted complies with the law and is not for an illegal purpose.
 - There is no reason why those *securities should not be granted *quotation.
 - An offer of the *securities for sale within 12 months after their issue will not require disclosure under section 707(3) or section 1012C(6) of the Corporations Act.
 - Note: An entity may need to obtain appropriate warranties from subscribers for the securities in order to be able to give this warranty
 - Section 724 or section 1016E of the Corporations Act does not apply to any applications received by us in relation to any ⁺securities to be quoted and that no-one has any right to return any ⁺securities to be quoted under sections 737, 738 or 1016F of the Corporations Act at the time that we request that the ⁺securities be quoted.
 - If we are a trust, we warrant that no person has the right to return the *securities to be quoted under section 1019B of the Corporations Act at the time that we request that the *securities be quoted.
- We will indemnify ASX to the fullest extent permitted by law in respect of any claim, action or expense arising from or connected with any breach of the warranties in this agreement.
- We give ASX the information and documents required by this form. If any information or document is not available now, we will give it to ASX before ⁺quotation of the ⁺securities begins. We acknowledge that ASX is relying on the information and documents. We warrant that they are (will be) true and complete.

Date: Friday, 28th July 2017

Sign here:

Company Secretary & CFO

Print name: Peter Vaughan



Appendix 3B – Annexure 1

Calculation of placement capacity under rule 7.1 and rule 7.1A for eligible entities

Introduced 01/08/12 Amended 04/03/13

Part 1

Rule 7.1 – Issues exceeding 15% of capital		
Step 1: Calculate "A", the base figure from which	h the placement capacity is calculated	
Insert number of fully paid *ordinary securities on issue 12 months before the *issue date or date of agreement to issue	101,420,624	
Add the following:		
 Number of fully paid *ordinary securities issued in that 12 month period under an exception in rule 7.2 Number of fully paid *ordinary securities issued in that 12 month period with shareholder approval Number of partly paid *ordinary securities that became fully paid in that 12 month period Note: Include only ordinary securities here – other classes of equity securities cannot be added Include here (if applicable) the securities the subject of the Appendix 3B to which this form is annexed It may be useful to set out issues of securities on different dates as separate line items 	2,960,793 (LR 7.2) 25,660,000 (LR 7.3)	
Subtract the number of fully paid *ordinary securities cancelled during that 12 month period	Nil	
"A"	130,041,417	

Step 2: Calculate 15% of "A"		
"B"	0.15 [Note: this value cannot be changed]	
Multiply "A" by 0.15	19,506,213	

Step 3: Calculate "C", the amount of placement capacity under rule 7.1 that has already been used		
<i>Insert</i> number of ⁺ equity securities issued or agreed to be issued in that 12 month period <i>not counting</i> those issued:	7,719,045	
Under an exception in rule 7.2		
Under rule 7.1A		
• With security holder approval under rule 7.1 or rule 7.4		
Note: This applies to equity securities, unless specifically excluded – not just ordinary securities Include here (if applicable) the securities the subject of the Appendix 3B to which this form is annexed It may be useful to set out issues of securities on different dates as separate line items		
"C"	11,787,168	

Step 4: Subtract "C" from ["A" x "B"] to calculate remaining placement capacity under rule 7.1		
"A" x 0.15 Note: number must be same as shown in Step 2	19,506,213	
Subtract "C" Note: number must be same as shown in Step 3	7,719,045	
Total ["A" x 0.15] – "C"	11,787,168 [Note: this is the remaining placement capacity under rule 7.1]	

Part 2

Rule 7.1A – Additional placement capacity for eligible entities		
Step 1: Calculate "A", the base figure from which the placement capacity is calculated		
"A"	130,041,417	
Note: number must be same as shown in Step 1 of Part 1		

Step 2: Calculate 10% of "A"	
"D"	0.10 Note: this value cannot be changed
Multiply "A" by 0.10	13,004,142

Step 3: Calculate "E", the amount of placement capacity under rule 7.1A that has already been used		
Insert number of *equity securities issued or agreed to be issued in that 12 month period under rule 7.1A	Nil	
Notes: This applies to equity securities — not just ordinary securities Include here — if applicable — the securities the subject of the Appendix 3B to which this form is annexed Do not include equity securities issued under rule 7.1 (they must be dealt with in Part 1), or for which specific security holder approval has been obtained It may be useful to set out issues of securities on different dates as separate line items		
"E"	Nil	

Step 4: Subtract "E" from ["A" x "D"] to calculate remaining placement capacity under rule 7.1A	
"A" x 0.10	13,004,142
Note: number must be same as shown in Step 2	
Subtract "E"	Nil
Note: number must be same as shown in Step 3	
Total ["A" x 0.10] – "E"	13,004,142
	[Note : this is the remaining placement capacity under rule 7.1A]

Appendix 3B

Page 11